UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign issuer

Pursuant to Rule 13a-16 or 15d-16 of the ~~Securities Exchange Act of 1934~~

~~For~~Securities Exchange ~~the~~Act ~~Month~~ of ~~May 2005~~1934

~~News~~For ~~Release~~the ~~dated~~Month ~~May 20,~~ of July 2005

News Release dated July 12, 2005

(Commission File. No 0-20390).

ID BIOMEDICAL CORPORATION

(Translation of registrant’s name in English)

1630 Waterfront Centre, 200 Burrard Street, Vancouver, BC V6C 3L6

(Address of principal executive offices and zip code)

Registrant’s Telephone Number, including area code: 604-431-9314

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:Form 20-F o 40-F ý

Indicate by check mark whether the registrant by furnishing the information contained in this Form 20 is also thereby furnishing the information to the Commission pursuant to Rule 12g3-F 2(b) under the Securities Exchange Act of 1934: Yes o ~~40-F~~ No ý

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes: o No: ý

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ID Biomedical Corporation

By:	/s/ Anthony F. Holler

Anthony F. Holler, Chief Executive Officer

Date: ~~May 30~~August 16, 2005

For immediate release

ID BIOMEDICAL ANNOUNCES WEBCAST OF 2005 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Vancouver, BC – May 20, 2005– ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it will be holding its Annual General Meeting of Shareholders at 2:30 pm (ET), on Thursday May 26, 2005 at the Fairmont Queen Elizabeth Hotel in Montreal, QC. A web cast of the meeting can be heard by accessing the Company’s website at www.idbiomedical.com. The web cast of the meeting will be archived and available on the Company’s website through August 22, 2005.

About ID Biomedical

ID Biomedical is an integrated biotechnology company dedicated to the development of innovative vaccine products. It operates in research, development, manufacturing, sales and marketing from its facilities in Canada and in the United States. ID Biomedical is dedicated to becoming a premier vaccine company with significant marketed products worldwide and an extensive pipeline in both clinical and preclinical development.

ID Biomedical has a leading position in the Canadian influenza market. It received a ten-year mandate from the Government of Canada in 2001 to assure a state of readiness in the case of an influenza pandemic and provide influenza vaccine for all Canadians in such an event. It also currently supplies approximately 75% of the Canadian government’s influenza vaccine purchases.

For further information on ID Biomedical, please visit the Company’s website at www.idbiomedical.com.

The information in this news release contains so-called “forward-looking” statements. These include statements regarding ID Biomedical’s expectations and plans relating to the integration of the vaccine business acquired from Shire, statements about ID Biomedical’s expectations, beliefs, intentions or strategies for the future, which may be indicated by words or phrases such as “anticipate”, “expect”, “intend”, “plan”, “will”, “we believe”, “ID Biomedical believes”, “management believes”, and similar language. All forward-looking statements are based on ID Biomedical’s current expectations and are subject to risks and uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the company’s ability to successfully integrate the Shire vaccine business; (ii) the company’s ability to successfully complete preclinical and clinical development of its products; (iii) the company’s ability to manufacture its products; (iv) the seasonality of the flu-vaccine business and related fluctuations in the company’s revenues from quarter to quarter; (v) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of its products for human testing; (vi) the company’s ability to enter into distribution agreements for its products, and to complete and maintain corporate alliances

relating to the development and commercialization of its technology and products; (vii) market acceptance of its technologies and products; and (viii) the competitive environment and impact of technological change and other risks detailed in the company’s filings with the Securities and Exchange Commission. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

For further information, please contact:

Investor Relations / Media

Dean Linden	Michèle Roy
(604) 431-9314	(450) 978-6313
dlinden@idbiomedical.com	mroy@idbiomedical.com

Filing Compare · ID BIOMEDICAL CORP